Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27779546 | 0.86 | SIGMAR1 (0.42) | SIGMAR1EPHX1EPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5610207 | 0.82 | SIGMAR1 (0.40) | SIGMAR1EPHX1CYP2D6EPHX2ALDH1A1 | |
| SCHEMBL7106803 | 0.75 | SIGMAR1 (0.39) | SIGMAR1EPHX1EPHX2ALDH1A1SMN1; SMN2 | |
| Dimethylamine SCHEMBL15938951 | 0.75 | SIGMAR1 (0.40) | SIGMAR1EPHX2ALDH1A1SMN1; SMN2HRH1 | |
| SCHEMBL15939017 | 0.74 | SIGMAR1 (0.63) | SIGMAR1CYP2D6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15939071 | 0.73 | SIGMAR1 (0.37) | SIGMAR1EPHX1EPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL16352696 | 0.73 | SIGMAR1 (0.64) | SIGMAR1EPHX2 | |
| SCHEMBL13430176 | 0.73 | SIGMAR1 (0.62) | SIGMAR1ALDH1A1 | |
| SCHEMBL13430183 | 0.72 | SIGMAR1 (0.63) | SIGMAR1EPHX2 | |
| Hydrochloric Acid SCHEMBL15940315 | 0.72 | SIGMAR1 (0.63) | SIGMAR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| CN-1208323-C | Alpha-substituted carboxylic acid derivatives | SANKYO CO (JP) | 2005-06-29 | — | — | CN | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| CN-1353694-A | Alpha-substituted carboxylic acid derivatives | SANKYO CO (JP) | 2002-06-12 | — | — | CN | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | SIGMAR1 950/4885EPHX1 2395/4885CYP2D6 601/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | SIGMAR1 950/4885EPHX1 2395/4885CYP2D6 601/4885 |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | SIGMAR1 3663/4885EPHX1 2426/4885CYP2D6 3704/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | SIGMAR1 3663/4885EPHX1 2426/4885CYP2D6 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.